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Background
To evaluate the administration, outcomes and ethical
issues of enforced clozapine in two patients with treat-
ment-resistant schizophrenia/schizoaffective disorder in a
forensic psychiatric setting, who were refusing oral cloza-
pine.
Methods
"Enforced clozapine" implied that if a patient refused oral
clozapine they received intramuscular clozapine at half
the expected oral dose. The case series involved 12 months
follow-up. Baseline and monthly measures included the
Brief Psychiatric Rating Scale (BPRS), Clinical Global
Impressions (CGI), Global Assessment of Functioning
(GAF), Insight and Treatment Attitudes Questionnaire
(ITAQ) and Quality of Life Self-Assessment Inventory
(QLS-100). Routine haematological, metabolic and car-
diac monitoring was informed by established clinical
guidelines. Statistical analysis utilized t-Tests and Pear-
son's correlation coefficient.
Results
Enforced clozapine was reasonably well tolerated with
rapid acceptance of oral clozapine. By 12 months, statisti-
cally significant improvements were seen in BPRS (p =
0.05), CGI (p = 0.04) and GAF (p = 0.03). Improvements
in ITAQ and QLS-100 were not statistically significant.
BPRS and CGI were strongly negatively correlated with the
length of time on enforced clozapine, clozapine dose and
clozapine serum levels. GAF, QLS-100 and to a lesser
extent ITAQ were positively correlated with those factors.
Conclusion
Enforced clozapine is a viable short-term treatment
option in treatment-resistant patients who are refusing
oral clozapine. It resulted in significantly reduced psy-
chotic symptoms, reduced dangerousness, a better quality
of life, improved insight into their illness and long-term
acceptance of oral clozapine. Unfortunately recent global
non-production of parenteral clozapine means that this
promising intervention in selected treatment-resistant
patients cannot be further evaluated and judiciously
implemented.
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